A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Solid Biosciences Announces Appointments to Management Team and Board of Directorson March 4, 2021 at 4:30 am
Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., (GLOBE NEWSWIRE) -- Solid Biosciences Inc.
- Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen)on March 3, 2021 at 10:49 pm
Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that it has been selected by Sarepta Therapeutics, Inc. as a limited ...
- Parent Project Muscular Dystrophy Awards $348,891 Grant to University of Florida Wellstone Centeron March 3, 2021 at 9:13 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), awarded the University of Florida (UF) Wellstone Muscular Dystrophy ...
- Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with ...on March 3, 2021 at 12:35 am
Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients ...
- Branford boy involved in high-tech therapy to halt progression of duchenne muscular dystrophyon March 1, 2021 at 4:15 am
When you first met the Herzogs in December 2019, they were starting a high-tech journey to help their son, Max, who suffers from duchenne muscular dystrophy.
- Rare Disease Day: How Bengaluru startup Hanugen Therapeutics is developing a cure for Duchenne Muscular Dystrophyon February 27, 2021 at 10:38 am
Bengaluru-based Hanugen Therapeutics is developing a solution for treating Duchenne Muscular Dystrophy, a fatal rare disease.
- FDA approves Sarepta drug for muscular dystrophy with rare genetic mutationon February 25, 2021 at 4:32 pm
The FDA decision gives Sarepta Therapeutics its third approved drug for Duchenne muscular dystrophy. The accelerated approval requires the biotech to conduct additional clinical testing to confirm the ...
- Another Duchenne Treatment Gets FDA Nodon February 25, 2021 at 2:32 pm
Casimersen (Amondys 45) is approved to treat Duchenne muscular dystrophy (DMD) patients with a confirmed mutation amenable to exon 45 skipping, the FDA announced Thursday. Like two other exon-skipping ...
- Sarepta wins new drug approval for patients with Duchenne muscular dystrophy, its third marketed treatmenton February 25, 2021 at 11:59 am
The FDA approved a new medicine from Sarepta Therapeutics that treats certain patients with Duchenne muscular dystrophy.
- Sarepta stock rises after FDA approves biotech's Duchenne MD treatmenton February 25, 2021 at 6:48 am
MarketWatch Sarepta stock rises after FDA approves biotech's Duchenne MD treatment . . Feb 25, 2021 8:48 PM UTC ...
via Bing News